DUARTE, Calif., August 2, 2022 /PRNewswire/ — Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for premature and critically ill infants, today announced that the neonatologist and breastfeeding advocate erin hamilton spenceMD, IBCLC, has been named director of clinical education and professional development.
Hamilton Spence brings more than 14 years of clinical experience as a board-certified neonatologist and lactation consultant to the Prolacta Medical Sciences Liaison team, having practiced in multiple hospital neonatal intensive care units (NICUs), including Cook Children’s Medical Center. and Baylor Scott & White Health. -Andrews Women’s Hospital.
In the Pediatrix Medical Group of Texas, Hamilton Spence has been an assistant neonatologist and lead physician for the Breastmilk Continuous Quality Improvement (CQI) initiative. At Cook Children’s Medical Center, Hamilton Spence currently chairs the Intensive Care Department. She founded the Gastrointestinal Rehabilitation Adaptive Care & Education (GRACE) team in 2020. Since 2010, Hamilton Spence has also served as Associate Medical Director of the NICU at Baylor Scott & White Health- Andrews Women’s Hospital leading QI efforts, including as physician main for multidisciplinary round as well as its Uber Preemie Team, serving infants less than or equal to 24 weeks of gestation, since 2016.
“Dr. erin hamilton spence is an experienced neonatologist with a proven track record of clinical leadership in some of the nation’s top NICUs,” said melinda eliot, MD, medical director of Prolacta. “Her extensive NICU and milk bank experience make her a perfect fit for the role of educating other neonatologists about the importance of an exclusive human milk diet (EHMD). Her leadership will be key in ensuring that the most seriously ill premature babies can benefit from human milk when they need it most.
A noted human milk researcher, Hamilton Spence is the author or co-author of studies published in the Journal of Perinatology, PLOS One, Gut, and the Human lactation magazine. She has presented her work at numerous conferences, including those of the Academy of Breastfeeding Medicine, the Pediatric Academic Societies, the American College of Obstetrics and Gynecology, and the American Association of Human Milk Banks. North America.
Hamilton Spence has an academic appointment as Clinical Assistant Professor at Texas Christian University Medicine School. She served as co-medical director and former president of the Breast Milk Bank of north texas and is a member of the Texas Breastfeeding Coalition. In addition, Hamilton Spence is a faculty member of the Scott & White Annual Conference of Neonatology (SWAN) and the NEO Conference.
“I am honored to join the Prolacta Health Sciences Liaison team. I have witnessed the life-saving value of Prolacta products in our NICUs. This position for Prolacta aligns with all of my larger interests in research, education and nutritional quality of human milk,” Hamilton Spence said. “Prolacta has led the way in advancing human milk-based nutritional care for premature infants in the NICU, and I am delighted to be making a difference beyond my own NICU for the most vulnerable infants and their families.”
A member of the Academy of Breastfeeding Medicine and the American Academy of Pediatrics, Hamilton Spence completed his fellowship and residency in pediatrics at the University of Texas Health Sciences Center – houston. He graduated from medical school at the University of Texas medical branch in Galveston.
About Prolacta Bioscience
Prolacta Bioscience® Inc. is a privately held global life sciences company dedicated to advancing the science of human milk® to improve the health of premature and critically ill infants. Prolacta’s 100% human milk-based nutritional products have been evaluated in more than 20 clinical studies published in peer-reviewed journals. To date, more than 80,000 premature babies have benefited from Prolacta nutritional products around the world.1 Established in 1999, Prolacta is the world’s leading provider of human milk-based nutritional products for hospital use and is also exploring the therapeutic potential of human milk in a broad spectrum of diseases. Prolacta maintains the strictest quality and safety standards in the industry for the detection, analysis and processing of donated human milk. Operating the world’s first pharmaceutical-grade human milk processing facility, Prolacta uses vat pasteurization and an FDA-reviewed, proprietary manufacturing process to ensure pathogen inactivation while protecting the nutritional composition and bioactivity of its products. based on human milk. Prolacta is a global company based in Duarte, Calif.and can be found online at www.prolacta.comin Twitter, Instagram, FacebookY LinkedIn.
- Estimated number of premature babies fed Prolacta products from January 2007 a december 2021; data on file.
SOURCE Prolacta Bioscience